Shanmuga Hospital Ltd

Financial highlights

• Revenue from operations: ₹4,743.61 Lakhs (FY2025-26).
• Total Income: ₹4,806.32 Lakhs.
• PAT: ₹421.06 Lakhs.
• EBITDA: ₹885.42 Lakhs.
• Basic EPS: ₹3.09.
• Net worth: ₹4,250.19 Lakhs.
• ROCE: 12.01%.
• IPO proceeds fully utilised; robotics funding completed.

Operations & clinical metrics

• In-patient admissions: 4,593; Out-patient visits: 44,898.
• Da Vinci Xi robotic system operationalised in 2025.
• Robotic surgeries: 100+; Surgeries performed: 2.5K+.
• Average length of stay: 2.6 days.

Technology & capabilities

• Investments in oncology, imaging and robotic technologies.
• Barriers to entry in robotics mitigated via Da Vinci Xi rollout.
• Shanmuga360 digital health platform under development to integrate services.

Capital structure & liquidity

• Authorised share capital: ₹14.00 Cr; issued: ₹13.613 Cr.
• Short-term borrowings: ₹314.43 Lakhs; Long-term borrowings: ₹359.35 Lakhs.
• Cash & bank balances: ₹192.52 Lakhs.
• IPO proceeds: ₹2,061.72 Lakhs; fully utilised.

Governance & compliance

• Board includes MD, EDs, and Independent Directors; AGM on 18 Sep 2026 via VC/OAVM.
• CS Anjana Anjan Maragatham appointed Secretarial Auditor for five years.
• Secretarial audit: no qualifications; governance processes robust.
• PoSH awareness training conducted; no complaints in FY2025-26.

ESG & CSR

• CSR obligation: ₹12.87 Lakhs; spent ₹12.94 Lakhs in FY25-26.
• CSR focus: education, healthcare, community development.
• Projects: Salem Ex-Servicemen Welfare Trust; Shanmuga Medical Research Foundation; Travellers Inn.
• Environmental initiatives: STP, Solar Power Plant, Biogas Plant.

Outlook & risks

• Healthcare growth in India expected 10-12% CAGR.
• Salem region presents expansion opportunities in tertiary care.
• Risks: regulatory shifts, inflation, talent retention, cybersecurity.

AGM Details

• AGM date 18 September 2026, 02:30 PM IST.
• Mode: VC/OAVM.
• Record/e-voting date: 11 September 2026.

Ordinary Business

• Adopt Audited Financial Statements for year ended 31 March 2026.
• Re‑appoint Mrs. Panneerselvam Jayalakshmi as Director.
• Re‑appoint Mr. Karuppiah Saravanan as Director.

Special Business

• Increase authorised share capital and amend MOA.
• Amend MOA main object to add two new clauses.
• Alter Articles: Definitions and capital/rights framework.
• Approve ESOP 2026 plan for up to 3.5 lakh options.
• Appoint CS Anuradha as Secretarial Auditor for five years.

Director Re‑appointments

• Mrs. Panneerselvam Jayalakshmi seeks re-appointment; retires by rotation.
• Mr. Karuppiah Saravanan seeks re-appointment; retires by rotation.

Dematerialisation/rematerialisation status

• No dematerialisation/rematerialisation requests were received for 01.04.2026 to 30.06.2026.

CGHS empanelment

• Office Memorandum dated 06.07.2026 confirms empanelment under CGHS.
• Tenure is three years from 19.06.2026.
• MoA executed on 19.06.2026; effective empanelment date 19.06.2026.
• Purpose: provide healthcare to CGHS beneficiaries, including government employees and pensioners.
• Empanelment should broaden patient base and strengthen CGHS presence.
• Not a related party transaction; no promoter/group interest.

Senior management resignation

• Dr. Mehak Jamwal, AVP-Operations, resigned due to personal circumstances.
• Cessation effective from close of business on June 4, 2026.
• She ceased to be a Senior Management Personnel of the company.

Meeting Details

• Board meeting scheduled for Monday, May 11, 2026.
• Meeting time was not disclosed.
• Venue: Registered Office, 51/24 Saradha College Road, Salem 636 007.

Key Agenda Items

• Approve audited financial results for quarter and year ended March 31, 2026.

Other Notes

• Trading window closed from April 1, 2026 until 48 hours after results declaration.